Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Dolezal is a 4-star analyst with an average return of 15.0% and a 43.63% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Ibio, Neurogene, and Rocket Pharmaceuticals.
In a report released on May 12, Bank of America Securities also maintained a Buy rating on the stock with a $44.00 price target.
Based on Oculis Holding’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $29.5 million. In comparison, last year the company had a GAAP net loss of $33.21 million
